Research programme: melanoma vaccine - MaxCyteAlternative Names: Melanoma immunotherapy - MaxCyte; Melanoma vaccine research programme - MaxCyte
Latest Information Update: 16 Jul 2016
At a glance
- Originator MaxCyte
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Malignant melanoma
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Malignant-melanoma in USA
- 15 Apr 2004 Preclinical trials in Malignant melanoma in USA (unspecified route)